文献速递临床试验与 GCP基础与转化研究

氢气吸入对肝切除术后患者生活质量影响的随机对照试验方案

Effect of hydrogen gas inhalation on patient QOL after hepatectomy: protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-10-21

本研究为随机、对照、双盲、优效性试验,纳入接受肝切除术的患者,随机分为氢气吸入组(A组)和空气吸入组(B组),比较术后第3天QoR40生活质量评分,并评估并发症、疼痛、饮食摄入、肝功能、炎症、尿8-OHdG及步数等指标。

要点

  • 氢气吸入可能通过选择性清除活性氧减轻肝切除术后肝功能障碍。
  • 主要终点为术后第3天QoR40生活质量评分。
  • 试验注册号jRCTs03220332,方案已获伦理批准。

核心结论

  • 氢气吸入对肝切除术后患者生活质量的影响尚待本试验验证。

研究设计与样本

  • 随机、对照、双盲、优效性试验,作为日本《临床试验法》下的特定临床试验实施。
  • 受试者为接受肝切除术的患者,随机分为氢气吸入组(A组)和空气吸入组(B组)。
  • 试验注册号jRCTs03220332,于2021年1月21日注册。

主要发现

  • 原文未报告试验结果,仅描述研究方案。

关键数值与推荐

  • 主要终点:术后第3天QoR40生活质量评分。
  • 次要终点:术后其他时间点QoR40评分、Clavien-Dindo并发症分级、NRS疼痛评分、饮食摄入量、肝功能、炎症水平、尿8-OHdG水平及计步器步数。

临床怎么用

  • 若试验证实有效,氢气吸入可能成为肝切除术后减轻氧化应激、改善生活质量的辅助治疗。

局限性

  • 本文为试验方案,尚无结果数据。
  • 氢气吸入在肝切除术后的应用此前无报道。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Molecular hydrogen had been considered inactive in vivo but is an antioxidant that selectively reduces highly toxic reactive oxygen species (ROS). Animal studies have reported that hydrogen gas inhalation helped alleviate cerebral and cardiac ischemia-reperfusion injuries. In humans, hydrogen inhalation therapy is presently approved as a treatment under Advanced Medical Care B in Japan (jRCTs031180352: limited to adult patients who suffered out-of-hospital cardiac arrest and are in a continuous coma) and its effectiveness is being examined in a clinical trial. The Japanese government has introduced the "Advanced Medical Care System" to promote the development of drugs and devices under governmental regulations. Advanced Medical Care B is a system designed for unapproved or off-label drugs or medical technologies used in a clinical trial setting. Hepatectomy is generally performed with repeated hepatic blood-flow occlusion and then reperfusion (ischemia and reperfusion). No report, however, has been made on ROS inhibition by hydrogen inhalation therapy or its effectiveness in post-hepatectomy patients. Hydrogen gas inhalation in the early stages after hepatectomy is anticipated to inhibit liver dysfunction by inhibiting ROS. METHODS AND ANALYSIS: This study is a randomized, controlled, double-blind superiority trial, which will be conducted as a "specified clinical trial" in accordance with the Clinical Trials Act in Japan. Trial registration was prospectively completed before the first participant was enrolled. The subjects will be patients who will undergo hepatectomy and will be allocated randomly into group A with hydrogen gas inhalation or group B with air inhalation after hepatectomy. The study will examine if hydrogen gas inhalation improves QOL of post-hepatectomy patients. The primary endpoint is patient QOL (score of a 40-item quality of recovery questionnaire, QoR40) on postoperative day 3 and the secondary endpoints are QoR40s besides that on postoperative day 3, grade of postoperative complications (Clavien-Dindo score), level of pain (Numerical Rating Scale (NRS)), amount of dietary intake, liver function, inflammation level, 8-hydroxydeoxyguanosine (urinary 8-OHdG) level, and number of pedometer-assessed steps. ETHICS AND DISSEMINATION: The study protocol has been approved by the Niigata University Central Review Board of Clinical Research. The findings of this study will be widely disseminated through peer-reviewed publications and conference presentations. TRIAL REGISTRATION: jRCTs 03220332 . Registered on 21 January 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kaibori M, Kosaka H. Effect of hydrogen gas inhalation on patient QOL after hepatectomy: protocol for a randomized controlled trial. Trials. 2021. PMID: 34674744. doi:10.1186/s13063-021-05697-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。